Targeting the Perivascular Microenvironment to Treat Serious Diseases

Mission & Values

Our mission is to improve the lives of patients by developing groundbreaking therapeutics that enhance the immune gatekeeping function of the perivascular microenvironment.

Our talented and dedicated team of scientists and professionals is continuously pushing the boundaries of scientific innovation, guided by our unwavering commitment to patients. We uphold the highest standards of quality and ethics and strive for excellence in every aspect of our work. We embrace change and challenge conventional thinking. Our diverse team, encompassing a wealth of backgrounds and perspectives, fosters a collaborative environment where individuals can thrive and be their authentic selves.


Montis Biosciences Team

Management Team

Gil Beyen

Gil Beyen

Chief Executive Officer and Executive Director

Read More
Iman El-Hariry

Iman El-Hariry

Acting Chief Medical Officer

Read More
Andrea Casazza

Andrea Casazza

Director Translational Science

Read More
Mohammed (Mo) Benkheil

Mohammed (Mo) Benkheil

Director Biology

Read More


Our Science

Welcome to Montis Biosciences, where innovation meets precision in the pursuit of transformative therapeutics. Montis is committed to pioneering cutting-edge solutions that specifically target the perivascular microenvironment in diseases driven by Immune-mediated Chronic Inflammation, with a primary focus on oncology and neurodegeneration.

Vascular and perivascular dysfunction often remains overlooked, yet actively contributes to the compromised immune microenvironment in diseases characterized by chronic Inflammation. At Montis, we recognize the potential of the vasculature to play a pivotal role in guiding and instructing a faulty immune composition within diseased tissues. The vasculature serves as a strategic immune interface between circulating blood and the underlying tissues. On one hand, it determines which immune cells gain entry into the tissue, while, on the other hand, a chronically inflamed vasculature further instructs faulty immune phenotypes in the perivascular space. Our mission at Montis is to develop antibody therapeutics that fine-tune the biology of the perivascular microenvironment, unlocking unprecedented benefits in the fields of oncology and neurodegeneration.

What sets Montis apart is our distinctive and patient-centric approach to target identification. We understand that each patient is unique, and our commitment to personalized medicine is at the core of everything we do. We leverage a robust human-based experimental platform that not only helps in uncovering disease vulnerabilities but also drives effective drug discovery programs. 

Backed by leading life science investors including Droia Ventures, Polaris Partners, ALSA Ventures, and Pfizer Ventures, Montis Biosciences stands at the forefront of innovation, driven by a shared vision to revolutionize healthcare.

Join us on this journey as we redefine the boundaries of therapeutic innovation, bringing effective solutions to those in need. 



Montis Biosciences is a young innovative biotech company based just outside Leuven, Belgium.

We are committed to developing cutting-edge therapies for the treatment of serious diseases and we want to make a positive impact on the lives of patients around the world.

Montis Biosciences creates a collaborative and supportive environment where employees are empowered to reach their full potential. We value teamwork, innovation and creativity and we are committed to fostering a culture of respect, diversity, inclusion and open communication.

Current career opportunities

There are no open positions for the moment, but feel free to send your spontaneous application to


Montis Biosciences

Arenberg Bio-Accelerator
Gaston Geenslaan 3
3001 Leuven